

Line 3 of the table FDIC expects no entities to file but has kept that line item with 0 burden in case needed for future IC renewal cycle.

#### General Description of Collection:

When a bank fails, the FDIC must provide depositors insured funds “as soon as possible” after failure while also resolving the failed bank in the least costly manner. The 12 CFR part 370 facilitates prompt payment of FDIC insured deposits when large insured depository institutions fail. The rule requires insured depository institutions that have two million or more deposit accounts (covered institutions), to maintain complete and accurate data on each depositor’s ownership interest by right and capacity for all of the covered institution’s deposit accounts. The covered institutions are required to develop the capability to calculate the insured and uninsured amounts for each deposit owner, by ownership right and capacity, for all deposit accounts. This data would be used by the FDIC to make timely deposit insurance determinations in the event of a covered insured depository institution’s failure. There is no change in the method or substance of the collection. The decrease of 42,483 hours from 52,652 hours in 2023 to the current estimate of 10,169 hours is due the elimination of the implementation burden for the Highest Complexity covered insured depository institutions (IDIs) and the reduction in the times per response.

#### Request for Comment

*Comments are invited on:* (a) Whether the collection of information is necessary for the proper performance of the FDIC’s functions, including whether the information has practical utility; (b) the accuracy of the estimates of the burden of the information collection, including the validity of the methodology and assumptions used; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. All comments will become a matter of public record.

Federal Deposit Insurance Corporation.

Dated at Washington, DC, on February 12, 2026.

**Jennifer M. Jones,**

*Deputy Executive Secretary.*

[FR Doc. 2026–03082 Filed 2–13–26; 8:45 am]

**BILLING CODE 6714–01–P**

#### FEDERAL MARITIME COMMISSION

[Docket No. 26–03]

#### Gator Fabrication Technology, LLC, Complainant v. Flador Global Logistics a/k/a Flador Global Uluslararası Taşımacılık Loj.Dıştic Ltd.Şti and NTG Air & Ocean, LLC, Respondents; Notice of Filing of Complaint and Assignment

Notice is given that a complaint has been filed with the Federal Maritime Commission (the “Commission”) by Gator Fabrication Technology, LLC (the “Complainant”) against Flador Global Logistics a/k/a Flador Global Uluslararası Taşımacılık Loj.Dıştic Ltd.Şti and NTG Air & Ocean, LLC (collectively, the “Respondents”). Complainant states that the Commission has jurisdiction over the complaint pursuant to the Shipping Act, 46 U.S.C. 41301, and over Respondents as having “acted as ocean transportation intermediaries or agents of ocean transportation intermediaries.”

Complainant is a limited liability company and shipper, with its principal place of business in Port Orange, Florida.

Complainant identifies Respondent Flador Global Logistics a/k/a Flador Global Uluslararası Taşımacılık Loj.Dıştic Ltd.Şti as having acted as an ocean transportation intermediary and non-vessel-operating common carrier with a place of business in İzmir, Türkiye.

Complainant identifies Respondent NTG Air & Ocean, LLC as a licensed ocean transportation intermediary with a place of business in Franklin Square, New York.

Complainant alleges that Respondents violated 46 U.S.C. 41102(c) and (d); 41104(a)(10) and (14); and 46 CFR 545.5. Complainant alleges these violations arose from Respondents withholding cargo, imposing detention charges, and asserting a maritime lien in order to coerce payment on an unrelated shipment, and other acts and omissions of Respondents.

An answer to the complaint must be filed with the Commission within 25 days after the date of service.

The full text of the complaint can be found in the Commission’s electronic Reading Room at <https://www2.fmc.gov/readingroom/proceeding/26-03/>. This proceeding has been assigned to the Office of Administrative Law Judges. The initial decision of the presiding judge shall be issued by February 12, 2027, and the final decision of the

Commission shall be issued by August 26, 2027.

(Authority: 46 U.S.C. 41301; 46 CFR 502.61(c))

Served: February 12, 2026.

**David Eng,**  
*Secretary.*

[FR Doc. 2026–03076 Filed 2–13–26; 8:45 am]

**BILLING CODE 6730–02–P**

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Health Resources and Services Administration

#### Request for Information: 340B Rebate Model Pilot Program

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services.

**ACTION:** Notice, request for information.

**SUMMARY:** The Health Resources and Services Administration (HRSA) administers section 340B of the Public Health Service Act (PHS Act), referred to as the “340B Drug Pricing Program” or the “340B Program.” HRSA is issuing this Request for Information (RFI) to gather input from interested parties regarding the potential use of rebates to effectuate the ceiling price under the 340B Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and the impacts on all stakeholders.

This RFI seeks comments on whether HRSA should implement a rebate model under the 340B Program and how best to operationalize any such rebate framework for stakeholders. The information collected through this RFI will assist HRSA in evaluating the operational, financial, and access to drugs for patients of a rebate model on covered entities, manufacturers, and other stakeholders across the drug supply chain.

**DATES:** Comments on this notice should be received no later than March 19, 2026.

**ADDRESSES:** Electronic comments should be submitted through the *Federal eRulemaking Portal*: <https://www.regulations.gov>. Follow the instructions on the website for submitting comments. Include the HHS Docket No. HRSA–2026–03042 in your comments. All comments received will be posted without change to: <http://www.regulations.gov>. Please do not include any personally identifiable or confidential business information you